TICKERNERD
Menu
KMTSKMTSHealthcare · Medical Instruments & Supplies

KMTS Stock Forecast: Kestra Medical Technologies Ltd. Price Predictions for 2026-2027

Last close, 5 Oct 2026
$28
+3.32% on the day

The 8 Wall Street analysts covering Kestra Medical Technologies Ltd. hold a median 12-month price target of $30 — +5.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 25 of 100 as at 3 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$1.6B
Ticker Nerd rank
25 / 100
Median analyst target
$30
Analysts covering
8
Revenue$28.6M+66.2% y/y
Operating income−$39.3M
Net income−$38.8M
Free cash flow−$28.4M
Quarterly, 8 quarters to 30 Apr 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+0.7%
1M
+11.0%
YTD
+6.9%
1Y
+14.2%
From 52W high
−0.4%
From 52W low
+58.6%
$18
$28
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

KMTS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Kestra Medical Technologies Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 3 Oct 2026
25 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
76
Revisions
63
Growth
56
Accruals
40
Size
38
Value
23
Volatility
20
Quality
16
Issuance
14

Momentum (76): The shares have been drifting up relative to others.

Issuance (14): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

KMTS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on KMTS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$25$30Jan 26Apr 26Jul 26Oct 26KMTSHigh $32Median $30Low $28

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says8 analysts
7 Buy1 Hold0 Sell
Low $28Median $30High $32

The green dot is the last close — the median target sits +5.9% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
15 Sept 2026BTIGReiteratesBuy$32
2 Sept 2026BTIGReiteratesBuy—
2 Sept 2026BTIGReiteratesBuy$32
10 Aug 2026JP MorganInitiatesOverweight$30
10 Aug 2026JP MorganInitiatesOverweight—
21 July 2026OppenheimerInitiatesPerform—
21 July 2026OppenheimerInitiatesPerform—
15 July 2026BTIGMaintainsBuy$30 → $32
15 July 2026BTIGMaintainsBuy—
9 Apr 2026Goldman SachsMaintainsNeutral—
7 Apr 2026BTIGReiteratesBuy—
25 Mar 2026BTIGReiteratesBuy—
18 Mar 2026BTIGReiteratesBuy—
15 Dec 2025Goldman SachsMaintainsNeutral—
12 Dec 2025Piper SandlerMaintainsOverweight—
12 Dec 2025Wells FargoMaintainsOverweight—
18 Nov 2025BTIGInitiatesBuy—
17 July 2025Wells FargoMaintainsOverweight—
16 Apr 2025Goldman SachsMaintainsNeutral—
31 Mar 2025Goldman SachsInitiatesNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. KMTS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

KMTS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 5 Oct 2026, Kestra Medical Technologies Ltd. returned +14.2% against +16.2% for the S&P 500, dividends included.

KMTS vs S&P 500, last 12 monthsTotal return, rebased to 100
708090100110120Jan 26Apr 26Jul 26Oct 26KMTSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

KMTS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
1
Fundamentals

Kestra Medical Technologies Ltd. (KMTS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−4.9×

Cheaper than 90% of US stocks

Price / sales
15.3×

Cheaper than 11% of US stocks

Price / book
7.3×

Cheaper than 13% of US stocks

EV / EBITDA
−11.3×

Cheaper than 85% of US stocks

Growth & margins
Revenue growth (YoY)
59.9%

Higher than 89% of US stocks

Earnings growth (YoY)
66.2%

Higher than 79% of US stocks

Gross margin
54.8%

Higher than 68% of US stocks

Operating margin
−121.6%

Higher than 13% of US stocks

Net margin
−140.4%

Higher than 4% of US stocks

Returns & dividend
Return on equity
−73.7%

Higher than 17% of US stocks

Return on assets
−29.2%

Higher than 14% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Kestra Medical Technologies Ltd. (KMTS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Kestra Medical Technologies Ltd. has a market value of $1.6B and an enterprise value of $1.5B.

  • Revenue in the twelve months to 30 Apr 2026: $95.1M. The latest quarter grew 59.9% year on year.

  • Net income over the same four quarters: −$131.6M, a −138.4% net margin.

  • Diluted earnings per share, trailing twelve months: $−2.42.

  • Free cash flow in the twelve months to 30 Apr 2026: −$117.1M, after $35.4M of capital spending.

  • Kestra Medical Technologies Ltd. spent $323K on dividends in the twelve months to 30 Apr 2026.

  • Shares outstanding: 58.4M.

  • Trailing P/E: −4.9×; forward P/E: −13.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Kestra Medical Technologies Ltd. employs 443 people — $215K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 Apr 2026 · market figures as at 4 Oct 2026

Data provided by Twelve Data

Peers

KMTS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Instruments & Supplies
CompanyMarket capTKN rank
KMTSKestra Medical Technologies Ltd.$1.6B
25
XRAYDentsply Sirona, Inc.$1.7B
90
AZTAAzenta, Inc.$1.8B
83
LMATLeMaitre Vascular, Inc.$1.8B
70
BLFSBioLife Solutions, Inc.$1.8B
91
STAASTAAR Surgical Co.$1.1B
70
ATRCAtriCure, Inc.$2.8B
94

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Kestra Medical Technologies Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest KMTS news & analysis

Kestra Medical Technologies Earns Five-Star Rating on Newsweek's List of America's Greatest Mid-Market Companies

GlobeNewsWire · 1 Oct 2026positive

Kestra Medical Technologies (Nasdaq: KMTS) received a five-star rating on Newsweek's list of America's Greatest Mid-Market Companies 2026. It was one of only 30 honorees to earn five stars and the only company in the Medical Equipment Manufacturing category to receive that rating.

Why it matters — This external recognition highlights Kestra as a standout among mid-market companies in its industry, which may bolster its reputation with investors and customers.

Kestra Medical: Strong Scaling Story, But Profitability Still On The Horizon

Seeking Alpha · 16 Sept 2026neutral

Kestra Medical Technologies is reported to be transitioning into a high-growth medtech platform with 60% year-over-year revenue growth and expanding gross margins, targeting mid-70s gross margins within 2–3 years. However, the company still shows a $44M net loss and $32M quarterly cash burn, and profitability remains distant despite raised FY27 guidance.

Why it matters — KMTS watchers would care because the report highlights both strong top-line scaling and unit economics improvements while underscoring that profitability is still pending, framing the current phase as a growth story with lingering financial headwinds.

Kestra Medical Technologies Posts Mixed Q1 Results, Joins Enova International, Dave and Buster's And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Benzinga · 15 Sept 2026negative

Kestra Medical Technologies reported mixed Q1 results and was listed among large stocks moving lower in Tuesday's pre-market trading session, alongside Enova International and Dave & Buster's. The report was covered by Benzinga against a backdrop of U.S. stock futures showing weakness.

Why it matters — KMTS watchers would track this because the company's mixed quarterly performance contributed to its shares declining in pre-market trading.

Kestra Medical Technologies, Ltd. (KMTS) Q1 2027 Earnings Call Transcript

Seeking Alpha · 15 Sept 2026neutral

Kestra Medical Technologies held its Q1 2027 earnings call, with a transcript of the event published on Seeking Alpha. The call covered the company's first-quarter financial results and management commentary.

Why it matters — KMTS watchers would care as the earnings call provides direct insight into the company's financial performance and outlook from management.

Kestra Medical Technologies, Ltd. (KMTS) Reports Q1 Loss, Tops Revenue Estimates

Zacks Investment Research · 14 Sept 2026neutral

Kestra Medical Technologies reported a first-quarter loss of $0.75 per share, which was wider than the Zacks Consensus Estimate of a loss of $0.61. The company's revenue figures topped analyst estimates for the quarter.

Why it matters — The mixed quarterly result—a wider-than-expected loss alongside a revenue beat—offers KMTS watchers a measure of how the company is tracking against analyst expectations.

FAQ

Frequently asked questions about KMTS stock

What is the KMTS stock price forecast for 2026-2027?

The 8 Wall Street analysts covering Kestra Medical Technologies Ltd. have a median 12-month price target of $30, with estimates ranging from $28 to $32. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is KMTS stock a buy right now?

Of the 8 analysts covering Kestra Medical Technologies Ltd., 7 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Kestra Medical Technologies Ltd. 25 out of 100 across roughly 4,600 US stocks as at 3 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank KMTS?

As at 3 Oct 2026, Kestra Medical Technologies Ltd. ranks 25 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (76 of 100).

Will KMTS stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +5.9% from the last close, and Ticker Nerd's factor model ranks Kestra Medical Technologies Ltd. 25 out of 100 as at 3 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the KMTS stock forecast for 2030?

No analyst covering Kestra Medical Technologies Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KMTS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $28 to $32 over the next 12 months.

How has KMTS stock performed over the past year?

Kestra Medical Technologies Ltd. returned +14.2% over the 12 months to 5 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Kestra Medical Technologies Ltd. do?

Kestra Medical Technologies, Ltd. is a commercial-stage wearable medical device and digital healthcare company focused on cardiovascular care.

What is the latest news on KMTS?

The most recent item we track (GlobeNewsWire, 1 Oct 2026): "Kestra Medical Technologies Earns Five-Star Rating on Newsweek's List of America's Greatest Mid-Market Companies". Kestra Medical Technologies (Nasdaq: KMTS) received a five-star rating on Newsweek's list of America's Greatest Mid-Market Companies 2026. It was one of only 30 honorees to earn five stars and the only company in the Medical Equipment Manufacturing category to receive that rating.

Company

About Kestra Medical Technologies Ltd.

Kestra Medical Technologies, Ltd. is a commercial-stage wearable medical device and digital healthcare company focused on cardiovascular care. Kestra Medical Technologies develops and commercializes the Cardiac Recovery System, an integrated platform designed to support patients at elevated risk of sudden cardiac arrest during vulnerable recovery periods. Its core offering is the ASSURE Wearable Cardioverter Defibrillator, which continuously monitors heart rhythms and can deliver defibrillation therapy when life-threatening arrhythmias are detected. The company also provides connected digital tools that support patient engagement, clinical workflow, and care coordination, helping clinicians access actionable cardiac data and oversee recovery more effectively. Based in Kirkland, Washington, Kestra Medical Technologies serves the medical technology market by combining diagnostic monitoring, therapeutic intervention, and data-driven support services into a single cardiovascular care ecosystem.

CEO Mr. Brian Webster · 443 employees · United States · https://kestramedical.com